包括年龄、性别、hTERT 和甲基化 RUNX3 在内的新指标有助于诊断早期胃癌

IF 2.5 3区 医学 Q3 ONCOLOGY
Oncology Pub Date : 2024-09-05 DOI:10.1159/000541173
Katsuhiko Nakamura, Yutaka Suehiro, Koichi Hamabe, Atsushi Goto, Shinichi Hashimoto, Yuki Kunimune, Akiyo Ishiguro, Naoko Okayama, Tomohiro Fujii, Yukiko Nakahara, Mitsuaki Nishioka, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Jun Nishikawa, Isao Sakaida, Taro Takami, Takahiro Yamasaki
{"title":"包括年龄、性别、hTERT 和甲基化 RUNX3 在内的新指标有助于诊断早期胃癌","authors":"Katsuhiko Nakamura, Yutaka Suehiro, Koichi Hamabe, Atsushi Goto, Shinichi Hashimoto, Yuki Kunimune, Akiyo Ishiguro, Naoko Okayama, Tomohiro Fujii, Yukiko Nakahara, Mitsuaki Nishioka, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Jun Nishikawa, Isao Sakaida, Taro Takami, Takahiro Yamasaki","doi":"10.1159/000541173","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>As the incidence of gastric cancer (GC) is increasing in East Asia including Japan, a simple blood test for early GC is needed as an alternative to upper gastrointestinal (UGI) endoscopy. We performed this study to address this issue.</p><p><strong>Methods: </strong>We collected serum samples from 319 participants comprising 225 healthy subjects without GC (control group) and 94 patients with early GC (early GC group). After evaluating copy numbers of serum hTERT and methylated RUNX3 (m-RUNX3) using the Combined Restriction Digital PCR (CORD) assay, which we developed, we assessed the diagnostic performance of hTERT and m-RUNX3 for early GC.</p><p><strong>Results: </strong>Serum levels of hTERT and m-RUNX3 were significantly higher in the early GC group than in the control group. The area under the curve (AUC) was 0.89 for hTERT and 0.78 for m-RUNX3. Multivariate logistic regression analysis revealed age, sex, hTERT copy number, and m-RUNX3 copy number to be independent factors for early GC. We then established a prediction formula and named it the ASTEm-R3 (age, sex, hTERT, and m-RUNX3) index. The AUC of the ASTEm-R3 index was 0.93 with a sensitivity of 79.7% and specificity of 91.1%.</p><p><strong>Conclusion: </strong>We demonstrated excellent performance of the ASTEm-R3 index using the CORD assay to detect early GC. This index might be a promising alternative to UGI endoscopy.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Novel Index Including Age, Sex, hTERT, and Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer.\",\"authors\":\"Katsuhiko Nakamura, Yutaka Suehiro, Koichi Hamabe, Atsushi Goto, Shinichi Hashimoto, Yuki Kunimune, Akiyo Ishiguro, Naoko Okayama, Tomohiro Fujii, Yukiko Nakahara, Mitsuaki Nishioka, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Jun Nishikawa, Isao Sakaida, Taro Takami, Takahiro Yamasaki\",\"doi\":\"10.1159/000541173\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>As the incidence of gastric cancer (GC) is increasing in East Asia including Japan, a simple blood test for early GC is needed as an alternative to upper gastrointestinal (UGI) endoscopy. We performed this study to address this issue.</p><p><strong>Methods: </strong>We collected serum samples from 319 participants comprising 225 healthy subjects without GC (control group) and 94 patients with early GC (early GC group). After evaluating copy numbers of serum hTERT and methylated RUNX3 (m-RUNX3) using the Combined Restriction Digital PCR (CORD) assay, which we developed, we assessed the diagnostic performance of hTERT and m-RUNX3 for early GC.</p><p><strong>Results: </strong>Serum levels of hTERT and m-RUNX3 were significantly higher in the early GC group than in the control group. The area under the curve (AUC) was 0.89 for hTERT and 0.78 for m-RUNX3. Multivariate logistic regression analysis revealed age, sex, hTERT copy number, and m-RUNX3 copy number to be independent factors for early GC. We then established a prediction formula and named it the ASTEm-R3 (age, sex, hTERT, and m-RUNX3) index. The AUC of the ASTEm-R3 index was 0.93 with a sensitivity of 79.7% and specificity of 91.1%.</p><p><strong>Conclusion: </strong>We demonstrated excellent performance of the ASTEm-R3 index using the CORD assay to detect early GC. This index might be a promising alternative to UGI endoscopy.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541173\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541173","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介随着包括日本在内的东亚地区胃癌(GC)发病率的上升,需要一种简单的早期胃癌血液检测方法来替代上消化道内窥镜检查。为了解决这个问题,我们进行了这项研究:我们收集了 319 名参与者的血清样本,其中包括 225 名无 GC 的健康受试者(对照组)和 94 名早期 GC 患者(早期 GC 组)。使用我们开发的联合限制性数字 PCR(CORD)检测法评估血清中 hTERT 和甲基化 RUNX3(m-RUNX3)的拷贝数后,我们评估了 hTERT 和 m-RUNX3 对早期 GC 的诊断性能:结果:早期 GC 组血清中 hTERT 和 m-RUNX3 水平明显高于对照组。hTERT和m-RUNX3的曲线下面积(AUC)分别为0.89和0.78。多变量逻辑回归分析显示,年龄、性别、hTERT拷贝数和m-RUNX3拷贝数是早期GC的独立因素。我们随后建立了一个预测公式,并将其命名为 ASTEm-R3(年龄、性别、hTERT 和 m-RUNX3)指数。ASTEm-R3 指数的 AUC 为 0.93,灵敏度为 79.7%,特异度为 91.1%:我们利用 CORD 检测法证明了 ASTEm-R3 指数在检测早期 GC 方面的卓越性能。结论:我们利用 CORD 检测法得出的 ASTEm-R3 指数在检测早期胃癌方面表现出色,该指数有望成为 UGI 内镜检查的替代方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Novel Index Including Age, Sex, hTERT, and Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer.

Introduction: As the incidence of gastric cancer (GC) is increasing in East Asia including Japan, a simple blood test for early GC is needed as an alternative to upper gastrointestinal (UGI) endoscopy. We performed this study to address this issue.

Methods: We collected serum samples from 319 participants comprising 225 healthy subjects without GC (control group) and 94 patients with early GC (early GC group). After evaluating copy numbers of serum hTERT and methylated RUNX3 (m-RUNX3) using the Combined Restriction Digital PCR (CORD) assay, which we developed, we assessed the diagnostic performance of hTERT and m-RUNX3 for early GC.

Results: Serum levels of hTERT and m-RUNX3 were significantly higher in the early GC group than in the control group. The area under the curve (AUC) was 0.89 for hTERT and 0.78 for m-RUNX3. Multivariate logistic regression analysis revealed age, sex, hTERT copy number, and m-RUNX3 copy number to be independent factors for early GC. We then established a prediction formula and named it the ASTEm-R3 (age, sex, hTERT, and m-RUNX3) index. The AUC of the ASTEm-R3 index was 0.93 with a sensitivity of 79.7% and specificity of 91.1%.

Conclusion: We demonstrated excellent performance of the ASTEm-R3 index using the CORD assay to detect early GC. This index might be a promising alternative to UGI endoscopy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信